Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats.
The purpose of this study was to explore the therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury. Middle cerebral artery occlusion was conducted in male Sprague-Dawley rats and 20mg/kg tetramethylpyrazine was injected intraperitoneally at different time points. Neurological deficit scores and brain infarction volumes were measured 72 h after reperfusion started. The expression of thioredoxin and thioredoxin reductase were examined at 6h and at 24h after reperfusion. Our results included the findings of a significant reduction in neurological deficit scores and infarction volume in the treatment group as compared to the control group. Ischemia/reperfusion injury resulted in a decrease in the expression of thioredoxin, while tetramethylpyrazine administration greatly elevated the expression of thioredoxin-1/thioredoxin-2 mRNA and thioredoxin reductase-1/thioredoxin reductase-2 mRNA. These findings suggest that administration of tetramethylpyrazine, within a 4h time period post-transient focal stroke, may reduce cerebral ischemic reperfusion damage. Moreover, the neuroprotective effect of tetramethylpyrazine may be mediated, in part, by an increase in genetic transcription of thioredoxin.
Zhu
Xiao-Ling
XL
Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Xiong
Li-Ze
LZ
Wang
Qiang
Q
Liu
Zhen-Guo
ZG
Ma
Xue
X
Zhu
Zheng-Hua
ZH
Hu
Sheng
S
Gong
Gu
G
Chen
Shao-Yang
SY
D000704:Analysis of Variance; D000818:Animals; D020520:Brain Infarction / Q000188:drug therapy; D004195:Disease Models, Animal; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D009460:Neurologic Examination; D011719:Pyrazines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy*; D013879:Thioredoxins / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011719:Pyrazines; D012333:RNA, Messenger; D014665:Vasodilator Agents; D013879:Thioredoxins; C017953:tetramethylpyrazine